Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,456

Document Document Title
WO/2018/071741A1
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...  
WO/2018/071679A1
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.  
WO/2018/050631A1
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...  
WO/2018/044963A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2018/026763A1
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutica...  
WO/2017/223349A1
The disclosure relates to antibacterial compounds having the Formula (I), where R1, R', A, B, X, s, and o are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical com...  
WO/2017/223243A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/193951A1
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.  
WO/2017/195216A1
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/195216A4
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/189831A1
Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its eti...  
WO/2017/180794A1
Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical com...  
WO/2017/168438A1
The present invention provides an industrially advantageous process for the preparation of pure allyl protected keto derivative of formula I, an intermediate of ezetimibe. by using a novel O-allyl amide derivative of formula II. wherein ...  
WO/2017/172802A1
The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as describe...  
WO/2017/167183A1
The present invention relates to the field of synthetic medicinal chemistry and provides a novel diaryl-β-lactam compound having significant anti-tumor activity, and a pharmaceutical use thereof. The present invention also comprises a u...  
WO/2017/158621A1
The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula (I).  
WO/2017/160925A1
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.  
WO/2017/156270A1
N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybut an-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-su...  
WO/2017/148518A1
The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions c...  
WO/2017/143628A1
The present invention relates to a method for preparing an industrially-produced method for preparing a hypolipidemic drug Ezetimibe and an intermediate thereof.  
WO/2017/140251A1
Provided are a method for preparing ezetimibe and an intermediate compound thereof. Provided is an economic method which is new, is easy to realize in industry, only includes very few steps and is established on a new intermediate. In th...  
WO/2017/131221A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/120124A1
Described are deuterium-substituted azetidine compounds of Formula (I), which are modulators of sphingosine 1 -phosphate receptor. Also described are pharmaceutical compositions comprising the deuterium-substituted azetidine compounds, a...  
WO/2017/117708A1
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing t...  
WO/2017/116558A1
The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and ...  
WO/2017/111172A1
The present invention provides compounds represented by formula (I) as cationic lipids, or pharmaceutically-acceptable salts or the like thereof.  
WO/2017/109095A1
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  
WO/2017/106064A1
The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositio...  
WO/2017/097732A1
The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/080966A1
Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula (I) structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substi...  
WO/2017/050990A1
The present invention relates to a compound with formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, the method for preparing same as well as the uses thereof, in particular the therapeutic use thereof, mainly in ...  
WO/2017/045648A1
The present invention relates to the field of chemical synthesis, and specifically to a preparation method for a deuterated compound. The preparation method comprises: converting a non-deuterated compound at least containing one structur...  
WO/2017/042233A1
The present application relates to novel azetidinimine of formula (I). Wherein R1-R6 are as defined in claim 1. The azetidinimine of the invention are useful as antibiotics and as inhibitors of a carbapenemases. The present invention thu...  
WO/2017/040537A1
Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject...  
WO2017010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO/2017/005950A1
The invention relates to β-lactam derivative compounds, capable of blocking thermoreceptor activation, in particular TRPM8 channels, and to the uses thereof as therapeutic agents for treating diseases of the respiratory system (coughing...  
WO/2017/006968A1
The present invention provides: a method for producing a 7H-pyrrolo[2, 3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2, 3-d]pyrimidine derivative; and a method for producing...  
WO/2017/004522A1
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2016/198374A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2016/198691A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein ASC is -N(R8)(R9)ASC-1 ASC-1 is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms ...  
WO/2016/185032A1
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more spec...  
WO/2016/172496A1
Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions ...  
WO/2016/172496A8
Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions ...  
WO/2016/172424A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)  
WO/2016/168058A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2016/168056A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2016/141279A1
Provided herein are small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK) having the structure of formula (I), wherein X and R1-R3 are defined in the specification. The compounds are useful for treating cancer and ...  
WO/2016/134292A1
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.  
WO/2016/123707A1
The present application relates to a novel process for the preparation of difluoromethyl ether-based derivatives from, for example, aliphatic and aromatic hydroxyl precursors, compositions comprising these compounds and their use, in par...  

Matches 1 - 50 out of 4,456